Paratek Pharmaceuticals corporate presentation deck
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, hosted an Investor Day on Tuesday, October 17, 2017, from 12:00 p.m. to 3:00 p.m. ET at the Lotte Palace Hotel in New York City.
During the Investor Day, Paratek’s management team and experts in the field of antibiotics development and infectious disease will discuss progress of the clinical development program and pre-commercialization activities for omadacycline.
The meeting featured presentations by key opinion leaders including:
- George Zhanel, Ph.D., University of Manitoba
- George Sakoulas, M.D., University of California San Diego
- Fredrick M. Abrahamian, DO, FACEP, FIDSA, David Geffen School of Medicine at UCLA
Paratek’s management team and experts in the field of antibiotics development and infectious disease discuss progress of the clinical development program and pre-commercialization activities for omadacycline.
Paratek Chief Commercial Officer Adam Woodrow presentation at RW Baird Investor Conference
Top-line findings from the omadacycline OASIS-2 ABSSSI trial
During the R&D day, Paratek’s management team and opinion leaders in the field of antibiotics development and infectious disease discussed progress of the clinical development program for omadacycline, including the following:
- Provided a company update
- Discussed the company’s efforts to advance clinical development for omadacycline’s use in UTI
- Reported results from additional registration enabling Phase 1 studies
- Clinical unmet needs in ABSSSI, CABP and UTI and the value of an IV and Oral treatment option
Slides from a keynote presentation by William O'Riordan, M.D., who discusses current therapeutic approaches to ABSSSIs. Members of the Paratek executive management team also provide an overview of the Company’s ongoing clinical development work with omadacycline, which is currently undergoing Phase 3 trials for the treatment of ABSSSIs and community acquired bacterial pneumonia (CABP).